Fresenius Kabi Breaks Into Brazilian Biosimilars Market
Strikes State-Private Adalimumab Deal With Fiocruz/Bio-Manguinhos And Bionovis
Fresenius Kabi has struck a deal with Brazilian organizations Fiocruz/Bio-Manguinhos and Bionovis to supply its Idacio biosimilar adalimumab rival to Humira for the next ten years.
You may also be interested in...
Fresenius Kabi CEO Michael Sen is set to replace Fresenius group chief executive Stephan Sturm from the start of October. He will remain head of Kabi until a successor is appointed.
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.
Chinese player Shanghai Henlius Biotech has out licensed semi-exclusive rights to some of its biosimilars in Brazil again, shortly after signing a major deal covering 16 Latin American countries.